Zhitong Finance App News, Luye Pharmaceutical (02186.HK) announced that the Drug Evaluation Center of the China National Drug Administration has officially accepted the marketing application for the new indications of the Group's Class 1 innovative drug Ruoxinlin® (torudivenlafaxine hydrochloride sustained-release tablets), which is intended to be used to treat widespread anxiety disorder. This is another milestone since the product was approved for marketing to treat depression in November 2022. As the marketing review of new indications progresses, Ruoxinlin® is expected to be the first serotonin, norepinephrine, and dopamine triple reuptake inhibitor (SNDRI) in China to treat generalized anxiety disorder, benefiting more patients.

Zhitong Finance App News, Luye Pharmaceutical (02186.HK) announced that the Drug Evaluation Center of the China National Drug Administration has officially accepted the marketing application for the new indications of the Group's Class 1 innovative drug Ruoxinlin® (torudivenlafaxine hydrochloride sustained-release tablets), which is intended to be used to treat widespread anxiety disorder. This is another milestone since the product was approved for marketing to treat depression in November 2022. As the marketing review of new indications progresses, Ruoxinlin® is expected to be the first serotonin, norepinephrine, and dopamine triple reuptake inhibitor (SNDRI) in China to treat generalized anxiety disorder, benefiting more patients.